A Phase 1 interventional study of DWP16001 Drug A and DWP16001 Drug C in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWP16001 Drug A and DWP16001 Drug C in healty adult volunteers.
The study design is a Randomized, Open-label, Oral, Single-dose, Two-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWP16001. Secondary endpoints were AUCinf, AUClast, Tmax, t1/2, CL/F, and Vd/F of DWP16001.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
☞ BMI (kg/m2) = Body weight (kg) / {Height (m)}2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 tablet, Oral, once daily single dose
Drug: DWP16001 Drug A
1 tablet, Oral, once daily single dose
Drug: DWP16001 Drug C
DWP16001 Drug A
DWP16001 Drug C
Cmax,ss of DWP16001
Peak Plasma Concetration of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
AUClast of DWP16001
The area under the plasma drug concentration-time curve of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
Tmax of DWP16001
Time at Cmax of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
T1/2 of DWP16001
Half life of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
CL/F of DWP16001
Apparent total clearance of the drug from plasma after oral administration of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
Vd/F of DWP16001
Volume of distribution of DWP16001
Time frame: At pre-dose (0 hour), and post-dose 0.25 to 72 hour.
Ran from Jul 2022 to primary completion in Aug 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →